DailyIQ
Last updated2 minutes ago

EXEL·Exelixis Inc.

$59.53
-0.29 (-0.48%)
Overnight$59.51-0.02 (-0.03%)
High
$60.00
Open
$60.00
Market Cap
15.05B
52W High
$61.66
Low
$58.59
P. Close
$59.53
P/E
17.49
52W Low
$33.76
Fwd P/E
13.92
DailyIQ Est.
$55.64
Inst. Ownership
49.4%
Short Interest
11.14%
Days to Cover
12.7
Technical Score (1D)
86
BULLISH
News Sentiment
72
BULLISH
With a Technical Score of 86, Exelixis Inc. (EXEL) sits in the upper tier of the momentum ranking on the 1D timeframe. The bullish bias and BUY signal follow from that rank, and trend strength reads as strong. Sentiment at 72 is aligned with the chart. Because the score is relative, it can stay high while the broader market falls, as long as EXEL holds up better than its peers. $57.24 is the near-term risk reference and $63.80 is the next upside marker if buyers keep pressing. A top momentum rank reflects the prior year of trading, so it changes gradually. Day to day, price levels give the earlier read: a decisive close below $57.24 would say more about near-term risk than the rank itself, while holding above it keeps $62.02 in play.
LOW TARGET
$41 -31.1%
2 analysts
MEAN TARGET
$55 -7.8%
18 analysts
HIGH TARGET
$70 +17.6%
8 analysts
PRICE RANGE
$41.00 - $70.00
SB / B / H / S / SS
4/8/14/1/1
DAILYIQ EST.
$55.64 (-6.5%)
Bought (1Y)
0 shares
$0
Sold (1Y)
67,000 shares
$3.4M
Beckerle Mary C-
Sell9,812 shares2026-08-10
Eckhardt Sue Gail-
Sell9,812 shares2026-06-01
WYSZOMIERSKI JACK L-
Sell3,925 shares2026-06-01
JOHNSON DAVID EDWARD-
Award/Grant19,133 shares2026-05-27
POSTE GEORGE-
Award/Grant8,367 shares2026-05-27
76/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Gross Margin
96.4%
Net Margin
33.7%
Revenue CAGR
19.9%
Current Ratio
3.56x
Debt / Equity
0.09x
Return on Equity
36.2%

EPS

EstBeatMiss
$0.64$0.71$0.78$0.86$0.93Q3'25Q3'26
QtrEstActual+/−
Q3'26$0.90 - -
Q3'25$0.67$0.78+16.2%

Revenue

EstBeatMiss
$588M$609M$630M$651M$671MQ3'25Q3'26
QtrEstActual+/−
Q3'26$662M - -
Q3'25 - $598M -

Market Data

EXEL Stock Snapshot

BULLISH86/100
$59.51−$0.02 (0.0%)
Market cap
15.05B
P/E ratio
17.5
Day range
$58.59 – $60.00
News sentiment
72/100 · Bullish
Analyst target
$54.87 (-7.8%)
Consensus
Hold · 28 analysts
52-week range+76.3% off low · -3.5% from high
$33.76$61.66
Price $59.51 DailyIQ Est. $55.64

Exelixis Inc. screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Behaviour On Record

What EXEL's own history says about today's numbers

Realized volatility (21d)
26.4% 9th pct
Below its peak
0.0%
vs 200-day average
+21.2%
Up days (1y)
53%

Exelixis Inc. is currently running 26.4% annualised volatility over the last 21 sessions. Measured against EXEL's own 13 years of daily returns rather than a market-wide average, that is the 9th percentile — unusually subdued by its own history, against a typical reading of 43.1%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

EXEL is at its running peak. Across 12 full years on file its median worst-drawdown-in-a-year was -34.6%, with the deepest at -84.4% in 2014 — so highs have historically been given back before they were extended.

Price sits +21.2% from its 200-day moving average. Against every other day in its history, that gap ranks at the 75th percentile — a somewhat wider gap than its own norm. Over the past year EXEL closed higher on 53% of sessions, and it is currently 3 sessions into a rising streak.

On October specifically: over 13 years of records, EXEL finished the month higher 5 of 13 times, with a median return of -6.8% and an average of -3.3%. Its strongest month historically has been November at +7.3% on average, its weakest March at -4.1%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: EXEL has opened more than 2% away from the prior close in 386 of 3,266 sessions (11.8% of the time), with the largest gaps running +40.7% and -27.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against EXEL's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of EXEL's sector?

Exelixis Inc. sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, EXEL ranks 13th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#13 of 15

Options Market

What is the options market pricing for EXEL?

CallsPuts

For Exelixis Inc.'s nearest expiry (2026-11-20, 37 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 0.8%. The options market is pricing roughly a ±0.2% move by that expiry — a range of about $57.44–$57.73.

Put/call ratio (2026-11-20)
0.00
ATM implied volatility
0.8%
Total open interest
10
Expected move by 2026-11-20
±0.2% ($57.44–$57.73)

Analyst Rating Changes

Are analysts turning bullish or bearish on EXEL?

RBC Capital most recently reiterated its rating on Exelixis Inc. to Sector Perform on Oct 9, 2026 with a price target of $51 (from $45). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Sector Perform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 9, 2026RBC CapitalMaintainedSector Perform$45 → $51
Oct 8, 2026RBC CapitalMaintainedSector Perform$46 → $45
Oct 7, 2026Truist SecuritiesMaintainedHold$52 → $54
Aug 19, 2026BMO CapitalInitiatedMarket Perform$54
Aug 6, 2026Truist SecuritiesMaintainedHold$56 → $52
Aug 6, 2026StifelMaintainedHold$47 → $51
Jul 23, 2026Morgan StanleyMaintainedEqual-Weight$50 → $53
Jul 14, 2026BarclaysMaintainedEqual-Weight$45 → $49
Jul 13, 2026Wells FargoMaintainedEqual-Weight$40 → $49
Jul 7, 2026RBC CapitalMaintainedSector Perform$43 → $46
Jul 7, 2026Truist SecuritiesMaintainedHold$54 → $56
Jul 2, 2026UBSMaintainedNeutral$43 → $52

ETF holders

ETFs holding EXEL

News Sentiment Analysis

Sentiment gathered from recent headlines

72/100
Strong NegativeNeutralStrong Positive
BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
RBC Capital Markets analysts concluded that Exelixis’ Zanzalintinib clinical trials across multiple cancer types are highly likely to succeed, projecting up to $2.5 billion in sales by 2035 for colorectal cancer alone. The analysts highlighted the company’s low clinical risk pipeline and seven programs that could provide stability over the next decade. Despite acknowledging that a single indication may not exceed $1 billion in sales, RBC maintained a sector‑perform rating and raised the price target to $51 from $45.
What did this article say?
RBC increased its price target for Exelixis (EXEL) to $51 from $45, reflecting confidence in the company’s prospects. The brokerage maintained a sector perform rating, indicating a positive outlook relative to peers. The upgrade suggests analysts expect continued growth and favorable market conditions for the biopharmaceutical firm.
What did this article say?
RBC Capital analyst Leonid Timashev raised Exelixis’ price target from $45 to $51 while keeping a Sector Perform rating. The upgrade reflects confidence in the company’s pipeline and recent clinical data. The move signals a modest upside potential for investors, though it does not represent a transformative catalyst.
What did this article say?
RBC Capital Markets reduced its price target for Exelixis from $46 to $45 while keeping a sector perform rating. The downgrade reflects a modest reassessment of the company’s near‑term earnings outlook. The change signals a slight headwind for investors but does not alter the overall positive view of the oncology sector. The adjustment is expected to modestly impact short‑term valuation expectations for Exelixis shares.
What did this article say?
RBC Capital analyst Leonid Timashev reduced Exelixis’ (NASDAQ:EXEL) price target from $46 to $45 while keeping the rating at Sector Perform. The downgrade reflects a modest view that the company’s valuation remains slightly over‑valued relative to peers. The move signals a cautious stance amid competitive pressures in the oncology space. No immediate catalysts were cited, and the rating change is unlikely to trigger a sharp market reaction.
What did this article say?
Exelixis (EXEL) reported a 51% year‑to‑date share gain, reflecting sustained investor confidence. The company’s stock traded around $58.44, remaining largely flat in short‑term moves despite the long‑term rally. Total shareholder return over the past year and three years reached 51.24% and 171.81%, respectively, underscoring the firm’s growing momentum. Analysts noted that the gains are largely price‑action driven, with no new product launches or regulatory milestones disclosed. The performance highlights Exelixis’s solid market position but does not signal an immediate catalyst for further upside.
What did this article say?
Exelixis (EXEL) has posted a 172.4% total return over five years, prompting analysts to evaluate whether current earnings can justify the stock’s valuation. The company’s oncology portfolio is expected to generate recurring earnings and cash flows, which could support a higher price relative to a Fair Ratio benchmark. Investors are weighing whether the earnings profile aligns with the stock’s recent performance and whether it warrants a revaluation.
What did this article say?
Exelixis (EXEL) completed $1.1 billion of share repurchases in 2025, cutting shares outstanding by 21% over three years and boosting earnings per share growth to 84.1% annually versus 73.7% net income growth. The company’s buyback program has added roughly ten percentage points to EPS growth each year, while the average repurchase price of $47.85 per share remained below the market price of $58.33. These actions have increased the value of each remaining share and positioned EXEL for continued upside as it maintains a strong cash flow base.
What did this article say?
ChartMill identified EXELIXIS as a strong technical candidate, awarding it a 10/10 technical score and an 8/10 setup rating. The stock sits within a tight base, suggesting a clear entry point for traders. The analysis highlights a defined breakout potential but does not indicate any fundamental catalyst or earnings impact. The technical assessment alone implies a modest positive outlook for short‑term price action.

Technical Analysis

Real-time indicators across multiple timeframes

86
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $6.47B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▼ Sell29,075,37711.49%$1.58B2026-08-07
Vanguard Group Inc▼ Sell25,490,44910.08%$1.12B2026-01-29
Renaissance Technologies LLC▼ Sell13,427,9935.31%$730.62M2026-08-13
AQR Capital Management LLC▼ Sell11,023,9434.36%$598.60M2026-08-14
Geode Capital Management, LLC▼ Sell7,650,3163.02%$416.32M2026-08-12
D. E. Shaw & Co., Inc.▲ Buy5,551,7472.19%$302.07M2026-08-14
Morgan Stanley▲ Buy4,519,6841.79%$245.92M2026-08-13
Invesco Ltd.▲ Buy4,495,6971.78%$244.61M2026-08-14
Two Sigma Investments, LP▲ Buy4,209,8611.66%$229.06M2026-08-14
Goldman Sachs Group Inc▲ Buy2,690,4891.06%$146.39M2026-08-14
Norges Bank▲ Buy2,688,8661.06%$146.30M2026-08-12
Bank of America Corp▲ Buy2,149,3970.85%$116.95M2026-08-14
Northern Trust Corp▼ Sell2,126,0940.84%$115.68M2026-08-13
JPMorgan Chase & Co▲ Buy1,298,9070.51%$71.08M2026-08-12
Millennium Management LLC▲ Buy1,218,7060.48%$66.31M2026-08-14
FMR LLC (Fidelity)▼ Sell1,147,9130.45%$62.46M2026-08-13
Gotham Asset Management, LLC▼ Sell892,6630.35%$48.57M2026-08-14
Marshall Wace, LLP▲ Buy831,5060.33%$45.24M2026-08-13
Janus Henderson Group plc▲ Buy913,8020.36%$39.20M2026-05-18
Wells Fargo & Company▲ Buy717,8400.28%$39.06M2026-08-14
Squarepoint Ops LLC▲ Buy473,7070.19%$25.77M2026-08-14
Man Group plc▼ Sell456,7610.18%$24.85M2026-08-14
Bridgewater Associates, LP▼ Sell400,8590.16%$21.81M2026-08-14
Citigroup Inc▲ Buy280,8500.11%$15.28M2026-08-03
AllianceBernstein L.P.▲ Buy344,2150.14%$14.76M2026-08-14
Q2 2026 flow:7.74M sh bought ($421.21M)5.67M sh sold ($308.07M)net +2.08M sh (+$113.15M)